Full-Time

Executive Director

Investor Relations

Entrada Therapeutics

Entrada Therapeutics

201-500 employees

Develops intracellular therapeutics using endosomal escape

Compensation Overview

$292k - $335k/yr

Boston, MA, USA

Hybrid

Hybrid role: remote with 1 day per week in-office at Boston HQ; travel ~25%.

Category
Business & Strategy (2)
,
Required Skills
Financial Modeling
PowerPoint/Keynote/Slides
Requirements
  • Bachelor’s degree required; advanced degree (PhD, MD, MBA, or MS in life sciences, biotechnology, or finance-related discipline) preferred.
  • 10+ years of progressive experience in investor relations within the biotechnology or pharmaceutical industry.
  • Experience supporting investor relations for a publicly traded biotechnology or pharmaceutical company, preferably NASDAQ-listed.
  • Experience in a clinical-stage or pre-commercial biotechnology environment strongly preferred.
  • Established relationships within the biotechnology buy-side and sell-side community strongly preferred.
  • Proven ability to develop and execute investor relations strategies that effectively reach and influence target audiences.
  • Strong financial acumen and financial modeling familiarity, with the ability to clearly communicate complex financial and clinical information to diverse external stakeholders.
  • Develop clear and compelling PowerPoint presentations for earnings calls, investor meetings, and board discussions that translate complex financial and strategic information into concise, visually compelling narratives.
  • Demonstrated ability to lead the use of investor relations software solutions to support investor engagement, shareholder monitoring and analytics.
  • Excellent written and verbal communication skills, with exceptional attention to detail.
  • Highly self-directed with exceptional project management and organizational skills, and the ability to prioritize multiple high-impact workstreams and deadlines.
  • Experience building, managing, and scaling investor relations capabilities across internal teams and external partners (e.g., agencies, vendors, consultants).
  • Demonstrated ability to work collaboratively and influence across functions and with senior executives to support the achievement of business objectives.
  • Deep understanding of the drug development lifecycle and the regulatory and disclosure environment for biopharmaceutical companies, including SEC and Regulation FD requirements.
  • Ability to travel approximately 25% as required to support investor engagement and key industry events.
  • This is a US based remote position, with preference given to local New England based candidates who can be in office 1 day per week to the Entrada Therapeutics Headquarters located in Boston, MA.
Responsibilities
  • Drive the strategic direction, planning, and execution of the investor relations function, including financial communications, while building and continuously strengthening a best-in-class investor relations program.
  • Serve as a trusted advisor to senior leadership by providing insight and guidance on investor messaging, communications effectiveness, market dynamics, and investor sentiment.
  • Act as the primary point of contact to the investment community, responding to external inquiries in an accurate, appropriate, and timely manner; establish and maintain strong relationships with biotechnology-focused buy-side and sell-side analysts and institutional investors.
  • Develop and maintain proactive engagement with investors and analysts to clearly communicate the Company’s long-term vision, clinical and platform strategy, differentiation, opportunity, risk factors, and key milestones.
  • Lead the development and coordination of financial and investor communications—including earnings releases, investor webcasts, investor presentations, Company corporate presentations and investor relations section of the Company website
  • Coordinate cross-functionally with Finance and Legal to support the timely and compliant execution of external financial disclosures and investor communications including periodic reports (Form 10-K and Form 10-Q), annual proxy statements and other reports.
  • Lead the Company’s participation in investment community events, including investor conferences, non-deal roadshows, analyst days, and targeted investor meetings.
  • Develop, track, and report key investor relations metrics in our Irwin investor relations system to assess program effectiveness and inform continuous improvement.
  • Monitor published research analyst reports covering the Company and analyze biopharmaceutical industry trends, investor perceptions, and competitor communications to inform strategic positioning and messaging.
  • Support capital markets activities, including potential financings and strategic transactions, in close partnership with the CFO and senior leadership.
  • Partner closely with the Chief Corporate Affairs Officer to ensure alignment with the broader corporate communications strategy and Entrada brand.
  • Manage external agencies and vendors, as needed, ensuring high-quality deliverables and disciplined management of external spend.
  • Ensure all investor communications and activities fully comply with SEC regulations and disclosure requirements, including Regulation FD and NASDAQ listing standards.
Desired Qualifications
  • Advanced degree (PhD, MD, MBA, or MS in life sciences, biotechnology, or finance-related discipline) preferred.
  • Irwin investor relations software experience preferred.
  • Experience preparing senior executives and Board members for investor engagement and earnings communications preferred.
  • Experience supporting equity offerings, capital markets transactions, or other strategic financings preferred.
  • Location preference for New England-based candidates who can be in the office 1 day per week to the Entrada Therapeutics Headquarters in Boston, MA preferred.

Entrada Therapeutics focuses on developing a new class of medicines to treat devastating diseases by delivering therapies inside cells. Its core technology, the Endosomal Escape Vehicle (EEV) platform, helps drugs escape from endosomes—cellular compartments that often trap or degrade treatments—so they can reach intracellular targets. The product pipeline centers on EEV-therapeutics, including candidates for Duchenne muscular dystrophy and other neuromuscular diseases, with ENTR-601-45 currently cleared by UK and EU regulators to begin clinical trials. What sets Entrada apart is its explicit emphasis on enabling intracellular delivery to access targets that were previously hard to treat, using a platform-agnostic delivery approach that can work with a range of therapeutics such as oligonucleotides. The company’s goal is to advance multiple EEV-therapeutics through clinical development to address rare and other hard-to-treat diseases and reach patients who need new treatment options.

Company Size

201-500

Company Stage

IPO

Headquarters

Boston, Massachusetts

Founded

2016

Simplify Jobs

Simplify's Take

What believers are saying

  • ELEVATE-45-201 and Cohort 2 data by end-2026 could demonstrate dose-dependent dystrophin improvements.
  • Early functional benefit signal in Time to Rise velocity suggests clinical relevance beyond biomarkers.
  • $255M cash runway extends operations into Q3 2027, enabling multiple trial readouts.

What critics are saying

  • ENTR-601-44 Cohort 1 achieved only 2.36% dystrophin increase versus 10% investor expectations.
  • Sarepta's Elevidys dominates DMD market with $400M+ 2025 sales and proven efficacy.
  • Cash burn of $39.7M quarterly forces dilutive fundraising or R&D cuts within 18 months.

What makes Entrada Therapeutics unique

  • EEV platform enables intracellular delivery to previously undruggable targets across multiple organs.
  • Multi-exon DMD pipeline (44, 45, 50, 51) addresses broader patient population than competitors.
  • Vertex partnership validates EEV platform for myotonic dystrophy type 1 co-development.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Entrada Therapeutics who can refer or advise you

Benefits

401(k) Company Match

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Unlimited Paid Time Off

Flexible Work Hours

Remote Work Options

Paid Vacation

Paid Sick Leave

Paid Holidays

Hybrid Work Options

Stock Options

Company Equity

Wellness Program

Mental Health Support

Gym Membership

Conference Attendance Budget

Professional Development Budget

Phone/Internet Stipend

Home Office Stipend

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-4%

2 year growth

1%
The Manila Times
Feb 4th, 2026
Entrada Therapeutics to Present at Upcoming Investor Conferences

Entrada Therapeutics to present at upcoming investor conferences. By GlobeNewswire February 4, 2026 BOSTON, Feb. 04, 2026 (GLOBE NEWSWIRE) - Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced the Company will participate in two upcoming investor conferences. Guggenheim Emerging Outlook: Biotech Summit 2026 Dipal Doshi, Chief Executive Officer, will participate in a fireside chat on Wednesday, February 11, 2026, at 4:00 p.m. Eastern Time in New York, NY. TD Cowen 46th Annual Health Care Conference Dipal Doshi, Chief Executive Officer, will participate in a fireside chat on Tuesday, March 3, 2026, at 2:30 p.m. Eastern Time in Boston, MA. Live webcasts will be available on the Investor Relations section of the Company's website at www.entradatx.com. Replays will be available on the Entrada website for 90 days following the events. About Entrada Therapeutics Entrada Therapeutics is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV(TM)-therapeutics are designed to enable the efficient intracellular delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Entrada is advancing a robust development portfolio of RNA- and protein-based programs for the potential treatment of neuromuscular, ocular and other diseases, leveraging next-generation EEVs, novel oligonucleotide sequences and an advanced protein engineering platform. The Company's lead oligonucleotide programs are in development for the potential treatment of people living with Duchenne muscular dystrophy who are exon 44, 45, 50 and 51 skipping amenable. Entrada has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1. Investor Contact Karla MacDonald Chief Corporate Affairs Officer Media Contact Megan Prock McGrath CTD Comms, LLC

Stock Titan
Sep 2nd, 2025
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Entrada has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.

DMDHelp
Aug 7th, 2025
Entrada Therapeutics doses first participant in Exon 44 skipping program; provides updates to other exon-skipping programs

Entrada Therapeutics, which received early funding from CureDuchenne, has provided updates on the status of several exon skipping programs.

The Manila Times
Feb 27th, 2025
Entrada Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

Entrada Therapeutics reports Fourth Quarter and Full Year 2024 Financial Results.

MarketBeat
Nov 28th, 2024
Massachusetts Financial Services Co. MA Invests $1.11 Million in Entrada Therapeutics, Inc. (NASDAQ:TRDA)

MA invests $1.11 million in Entrada Therapeutics, Inc. (NASDAQ:TRDA).